Ablating short-segment Barrett esophagus: What’s your weapon of choice?

August 7th, 2011

Ablating short-segment Barrett esophagus: What’s your weapon of choice?

The first cases of Barrett esophagus (BE) ablation in the late 1980s used YAG and Argon laser. Since then, a myriad of ablation techniques have been described, including multipolar electrocautery (MPEC), argon plasma coagulation (APC), cryotherapy, radiofrequency ablation (RFA), and endoscopic mucosal resection (EMR). Each technique has had its advocates, and some of the techniques appear to have certain advantages in certain types of BE: e.g., long segment, nodular, etc.

Most cases of BE are short segment, and most neoplastic cases do not have nodules or erosions. So the question I would like to see discussed is: In a patient with 1–2 cm of otherwise featureless flat but neoplastic BE:

What ablation technique would you use, and what do you feel makes this technique advantageous?

What would be your second option, and when would you employ it?

Do you use more than one technique, and, if so, which ones do you use and why?

What are the most common complications you see with BE ablation?

What is your overall success at complete BE elimination?

We look forward to your comments.

Categories: Patient care
Tags: Barrett esophagus

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia March 12, 2026

Myelosuppression has long been the major dose-limiting toxic effect of chemotherapy in treating cancer. Reducing the severity of chemotherapy-induced myelosuppression addresses two priorities. One is to prevent myelosuppressive complications — neutropenia and thrombocytopenia, in particular — that can lead to febrile neutropenia, infection, and bleeding. A second priority centers around...

Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention — IARC Working Group Report March 12, 2026

The IARC Working Group summarizes guidance on H. pylori screen-and-treat programs for gastric cancer prevention and concludes that prevention is the most effective strategy amid a rising global burden.

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia March 12, 2026

In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16).

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma March 5, 2026

Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events.

The Growing Success of Medicare Drug-Price Negotiation February 26, 2026

Medicare will achieve greater savings on the 15 drugs in its second round of price negotiations than it did in the first round. Despite new challenges, the effort should continue to pay growing dividends.

Gut Check on Gastroenterology Archive

Gut Check on Gastroenterology, an NEJM Journal Watch blog focusing on issues in clinical gastroenterology, was active from 2008 to 2014. This archive contains all posts and discussions from Gut Check’s history.

August 7th, 2011